A DNA sequence-selective antitumour agent (SP-2001)
is in Phase I clinical trials in the USA
and UK, and other DNA-interactive agents and prodrugs are in
pre-clinical development. In addition, antibacterials, antivirals
and antiparasitics are attractive targets for this DNA sequence
technology. Functional biology studies will inevitably reveal
thousands of novel therapeutic gene targets over the coming
decades.
A DNA sequence-selective antitumour agent (SP-2001) is in Phase
I clinical trials in the USA and UK, and other DNA-interactive
agents and prodrugs are in pre-clinical development. In addition,
antibacterials, antivirals and antiparasitics are attractive
targets for this DNA sequence technology. Functional biology
studies will inevitably reveal thousands of novel therapeutic
gene targets over the coming decades.
If you can't see the animations above, you will need the flash player.
Click here to
download
